Erythropoietin Therapy for Children With Cerebral Palsy

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomized placebo-controlled trial aims to investigate the efficacy and safety of erythropoetin for children with cerebral palsy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bundang CHA Hospital
• Collaborator: LG Life Sciences
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Cerebral Palsy

• Abnormal Muscle Tone

• Abnormal Brain MRI

• Willing to Comply with All Study Procedure

Exclusion Criteria:

• Known Genetic Disorder

• Other Etiologies Contributing Developmental Delay

• Coagulopathy

• Initial high Erythropoietin level in Serum

• Previous Erythropoietin Treatment before 3 months

• Presence of Drug Hypersensitivity Related to the Study Remedy

• Intractable Seizure Disorder

• Poor Cooperation of Guardian including Inactive Attitude for Rehabilitation